Lipocine Inc.
LPCN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $11 | -$3 | $1 | $16 |
| % Growth | 492.8% | -670.2% | -96.9% | – |
| Cost of Goods Sold | $0 | $10 | $9 | $8 |
| Gross Profit | $11 | -$13 | -$8 | $8 |
| % Margin | 100% | 456.9% | -1,611.4% | 52.5% |
| R&D Expenses | $7 | $0 | $0 | $0 |
| G&A Expenses | $5 | $5 | $4 | $5 |
| SG&A Expenses | $5 | $5 | $4 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12 | $5 | $4 | $5 |
| Operating Income | -$1 | -$18 | -$12 | $3 |
| % Margin | -10.3% | 629% | -2,423.9% | 19.5% |
| Other Income/Exp. Net | $1 | $2 | $1 | -$4 |
| Pre-Tax Income | $0 | -$16 | -$11 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$16 | -$11 | -$1 |
| % Margin | 0.1% | 573.6% | -2,151.7% | -3.9% |
| EPS | 0.002 | -3.14 | -2.15 | -0.19 |
| % Growth | 100.1% | -46% | -1,031.6% | – |
| EPS Diluted | -0.002 | -3.14 | -2.05 | -0.12 |
| Weighted Avg Shares Out | 5 | 5 | 5 | 3 |
| Weighted Avg Shares Out Dil | 5 | 5 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$18 | -$11 | -$0 |
| % Margin | -9.9% | 628% | -2,144.3% | -2.7% |